FDA Publishes Rejection Letters to Increase Transparency in Drug Approval Process
The FDA released over 200 letters sent to drug companies regarding rejected medicines, focusing on transparency by compiling these communications, including 14 published for the first time, covering decisions from 2020 to 2024, with some redactions for privacy.